Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-1R2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-1R2 ECD-Fc Fusion Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. HEK293 Expressed. |
View IL1R2 Products |
| Gene Delivery | IL-1R2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and conformation-dependent screening. |
View IL1R2 Products |
| Benchmark Ab | Anti-IL-1R2 Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View IL1R2 Products |
| Validator | IL-1R2 siRNA Set Target-specific knockdown pool for validation of target specificity. |
View IL1R2 Products |
| Related Target A | IL-1R1 (CD121a) Critical counter-screening target to ensure selectivity of IL-1R2-specific therapeutics. |
View IL1R1 Products |
| Related Target B | IL-1 beta (IL1B) Primary ligand of IL-1R2; essential for ligand-blocking and decoy-receptor competition assays. |
View IL1B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity over signaling receptor IL-1R1 | High-purity IL-1R1 and IL-1R2 recombinant proteins available for parallel SPR/BLI counter-screening. |
| Cross-species ortholog evaluation | Human, Cynomolgus, and Mouse IL-1R2 orthologs with verified sequence identity and high purity (>95%). |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live IL-1R2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-1R2 therapeutics is intensifying, with major players shifting focus from traditional systemic anti-inflammatory agents to tumor microenvironment (TME) modulation. Because IL-1R2 acts as a natural decoy receptor that sequesters IL-1 (thereby suppressing IL-1-mediated pro-inflammatory and anti-tumor immune responses), targeting IL-1R2 represents a novel immune checkpoint strategy. As first-generation therapies targeting the IL-1 pathway reach the clinic, the next wave of R&D is targeting IL-1R2 to selectively deplete immunosuppressive myeloid cells and regulatory T cells (Tregs) in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Innate Pharma, Biopharma Consortia | Solid Tumors (Oncology), Inflammatory Diseases | Selectivity Screening (Need highly purified IL-1R2 vs IL-1R1 proteins) |
| Antibody-Drug Conjugates (ADCs) | Oncology-focused Biotechs | Ovarian Cancer, Breast Cancer | Internalization Assay (Need high-purity ECD-Fc and stable cell lines) |
| Recombinant Decoy Proteins | Immunology Specialists | Rheumatoid Arthritis, Autoimmune Diseases | Ligand Binding Affinity (Need bioactive-grade IL-1 beta and IL-1R2) |